there are already sixteen trade names for para-amino-benzene-sulphonamide. Sulphanilamide was suggested by my colleague, Dr. Fuller, as a suitable abbreviation for para-amino-benzene-sulphonamide, and it has met with acceptance as a suitable name for this class of substance. The name " prontosil album " has also been given to sulphanilamide and has caused, and will cause, considerable confusion. By registering the name " prontosil album ", the Germans, despite the debt of gratitude we owe to them for their original prontosil, have done a great dis-service to the progress of medicine, since so frequently now the term " prontosil " is used wvithout any (Illalification, making 'confusion worse confounded'.
To return to the action of sulphanilamide. It was showrn that this drrug had remarkable antibacterial properties not possessed by red prontosil. These properties are different from those of the ordinary antiseptics which kill microbes well in water, less well in serum, and hardly at all in blood. With sulphanilamide the reverse is the case. It kills streptococci very well in blood, nearly as well in serum, but very little in water. The blood of patients treated with sulphanilamide also shows a greatly increased power of disposing of the streptococci. This latter effect has been challenged by some of the German workers. If you mix blood, streptococci and sulpha.nilamide, in a stoppered tube with limited aeration, you get the effect I have described. The control blood kills very few streptococci, while the sulphanilamide blood kills enormous numbers. If the experiment is carried out under conditions permitting of free aeration you get a rather different result. This may explain the divergence between our results and those of the German workers. It is conceivable that these drugs act as '' internal antiseptics " in the body and that there is a direct killing of streptococci in both blood and tissues, but we cannot be sure of that.
Red prontosil does not possess these antibacterial effects in vitro. Nevertheless, one can demonstrate an increased killing power towards streptococci in the blood of patients treated with red prontosil (i.e. the soluble form). This phenomenon, however. appears later, after the lapse of many hours. The explanation of this has been given by my colleague, Dr. Fuller, who has shown that the red prontosils are, in large part, converted by the body into sulphanilamide and excreted as such. This is, in my opinion, the most important fact we have with regard to these drugs.
A further important fact, to the elucidation of which Dr. Fuller has again largely contributed, is the extreme diffusibility of red prontosil and sulphanilamide, as a result of which they rapidly reach the blood, urine, cerebrospinal fluid, and milk. This is probably an important factor in their therapeutic action. Furthermore, these suibstances are of a low order of toxicity in man and animals.
During the last few months substances have been described by Buttle and bis co-workers (1937) which are of special interest because, although they differ considerably from sulphanilamide and are almost certainly not converted into that substance in the body, they have a very high curative activity in streptococcus-infected mice. Now I shall deal with the evidence of the effectiveness of these substances in man.
Ouir Chairman, Dr. Tidy, has described this as a fact, and I think all the world is accepting it as a fact, but it is right that we should preserve a critical attitude. I will show you the results we have obtained at Queen Charlotte's Hospital and discuss them briefly. They refer to puerperal fever, but this is not to be regarded as an infection distinct from medical and surgical sepsis. It is nothing more than the infection of a wound by the same strains of haemolytic streptococci as those causing surgical sepsis, cellulitis, tonsillitis, scarlet fever, and many other conditions.
We have taken the figures for the five years before the introduction of prontosil as a standard of reference. During these five years we did not consider that there was any specific treatment worthy of the name. The death-rate for this period did not vary very much, averaging 2288%. During the whole of 1935 the death-rate was as high as ever; from the beginning of 1936, when we began to use red prontosil, up to the 3 Section of Medicine with Section of Therapeutics and Pharmnacology 151 present, our death-rate has been 4115-5O. Sixty-five cases have been treated with the twvo red prontosils in combination, andl 115 cases with streptocide, a preparation of' sulphanilamide. Twenty-one cases did not require treatment. Along with the fa,lling death-rate, the course of the fever has changed considerably. During these last tN-o vears the temperatures have usually come down in two or three days after treatment with these drugs, and stayed down, instead of gradually coming dowrn andl oscillating for a w-eek or two. Parametritis, which formerly w-as the bugbear of our puerperal fever wards, has now almost completely disappeared, except for cases due to infections other than hbemolytic streptococci.
Are we justified then in considering that these results--hich cannot be doubted a,re due to the drug ? Or may there be any other explanation ? Mr. G. F. Gibberd, in a, thoughtful paper given at the British Medical Association at Belfast, discussed whether there might have been a diminished ' invasiveness" of the streptococcus (iiring this period of improvement.
Such a change wkould halve the same kind of effect on the figures as we have seen, and during the last fifty years a similar change has occurre(d in the course of scarlet fever. If, however, it has also happened in puerperal fever it has happened rather suiddenly and coincides with the introduction of prontosil. There have been slightly f'ewer cases with positive blood culture, fewer cases with signs of general peritonitis, but if we have a drug wrhich is effective this is to be expected. It becomes difficult, therefore, to be sure about diminished " invasiveness ".
To obtain further evidence oIn the point, my colleague, Dr. Fry, has selected for study all the cases showing positive evidence of "invasiveness " during the past seven years, i.e. cases in which haemolytic streptococci were demonstrated in the bloodstream. From 1932 to 1935 such cases showed a 710% mortality, while for the 22 cases in the last two years there is a case mortality of only 27-3%. It is very suggestive that, in spite of these cases belonging to the invasive class, the drug has had an effect. Furthermore, Mr. Gibberd thought it right to take into account only our puerperal fever results, from w%hich it is difficult to draw an absolutely definite conclusion. But if you take all the evidence, as we should, it seems to me to establish an extremelv high degree of probability. By i all the evidence " I mean evidence that animais are certainly cured the fact of the greatly increased bactericidal power of the blood; and thirdly, the fact that cases are now recovering which formerly did not recover, or at least under circumstances which make it almost impossible to believe that the drug was not responsible for the recovery.
One such case has been described by Purdie and Fry (1937) . It was that of a woman w-ho had a continuous suppuration, due to hemolytic streptococcus infection, for a period of three years. The streptococci disappeared entirely within three weeks from the commencement of treatment, and in six weeks the patient was completely healed for the first time in three years. Other cases of this type, which are valuable as evidence, are cases of meningitis. Gray, in America, from a careful study published in 1935, concluded that the recovery from haemolytic streptococcus meningitis was less than 300. He found only 66 such cases in the literature for the whole of this cenitury. In the last few months there have been nine cases described in English and American literature alone,l and this is strong confirmatory evidence that these xsubstances do act on the human suibject.
In medicine we habitually have to act on probability rather than on complete certainty; the evidence in regard to these new compounds seems to me amply sufficient for such a basis of probability. We may well keep our minds open, however, to the possibility that we have attributed too much to the drugs and too little to spontaneous recovery.
There are two points I should like to make, in passing, with regard to the results at 1 POSTSCRIPT.-Since the date of this Discussion a further search of the literature has revealed a total of 26 cases which have recovered after treatment by sulphanilamide or the red dyes. Queen Charlotte's Hospital. Firstly, we have obtained no striking evidence of any benefit from these drugs in infections other than those due to haemolytic streptococci -with the possible exception of staphylococcal infections. This statement should not be understood to include the puerperal infections of the urinary tract by B. coli, but only infections of the genital-tract tissues. Secondly, and this is of interest, we have been trying in the past year to compare the results obtained with sulphanilamide (streptocide) with those obtained with red prontosil previously. Results with the former have been satisfactory; the death-rate has been a little, but not very much.
higher; fever has subsided in much the same way as with red prontosil, but the fall is not always quite so spectacular. There have been a few very slight cases of parametritis. We feel that although the results have been satisfactory with sulphanilamide, they have not been quite so impressive as those with red prontosil. I do not want to stress this conclusion-possibly further experience will reverse it. Why it shouli be so I do not know; in animals the opposite is the case. We are publishing our report on the subject (Colebrook, Purdie and others (1937) ).
If I may digress for a motnent, it is to say that if we are getting nothing more out of prontosil and sulphanilamide, I feel that it is a great gain that we have been pitch-forked into this question of the difficulty of assessing the results of new remedies. In the next few years we shall be deluged with new compounds, and we have to sit down to consider the problem as how to know whether one is 20% or 5000 better thanl the other.
The medical " man in the street's " idea that you can take alternate cases is not good enough. I do not know how it is to be done, but it is a question which needs serious thought. One point I would make is, that our experience at Queen Charlotte's has shown the great value of having units for this purpose such as we have at that hospital a small hospital with a comparatively large laboratory equipped for attacking the problem from several sides, and staffed with people who have nothing to think about but the one problem. Progress in medicine would be faster if we had more " workshops " as one might call them, of the type we have at that hospital, witi plenty of people in the laboratory for working out the several problems, because they do require an enormous amount of work.
I had intended to say something about the action of these s;ubstances, but I shall not. I think Dr. Buttle will have something to say as to what little actuallv is known about this.
Instead, I shall deal with the toxic effects of these drugs, a subject of more practical interest. It seems almost inevitable that new drugs have to go through two phases before We can see them in their true perspective as to toxic effects. The first phase is that in which the toxic effects receive too little emphasis in the medical press : in the second phase they receive too much. With regard to these particular drugs we are in the second stage at present, and medical journals are flooded with reports of one, two, or three cases showing toxic effects, and nothing is said of the hundre(ds of cases which show no such effects. I will tell you what our experience has been
We have treated 150 cases with sulphanilamide for a perio(d of one to txx o weeks and about 50 cases for shorter periods, i.e. one or two days. We have treated nearly 70 cases with red prontosil. The most prominent toxic effects we have observed have been cyanosis, although sulphate purgatives have been rigorously avoided. More than 5000 of the cases treated with sulphanilamide have shown some degree of cyanosis in the majority, of slight degree. In the 58 cases we are recording in our paper there was sulphaemoglobin found in 13, methaemoglobin in another 24, the two together in 8 cases. Methoemoglobin has been more prominent. In eight cases showing some cyanosis we could find neither methaemoglobin nor sulphaemoglobin. There were three cases in which the cyanosis was accompanied by an alarming, amount of prostration, so severe that the drug had to be discontinued in all three. One of these three was having very large doses. Whether the prostration was intimately associated with the cyanosis I do not know. All were heavily infected cases; one had general peritonitis and septicaemia. Apart from this incidence of prostration, cyanosis did not appear to us to be a serious matter.
Secondly, in some cases we saw what the Americans have been describing as drug fever "; this is a type of fever we have seen in 6 or 7 cases out of 100. There would be nothing to suggest from the clinical signs and symptoms that the case was having a recrudescence of the disease, but the temperature rose and we stopped the (Irug, and on stopping the drug the temperature fell. Long and Bliss (1937) have produced fever by injecting 2-5 grm. of red prontosil, and last winter, in America, I saw two or three patients who got fever every time they had sulphanilamide.
We must therefore accept the fact that some patients will have fever due to the (1rug. In about 20 cases there has been recurrence of fever a few days after we stopped the drug and this has been attributed to some recrudescence, but in every case on resuming drug treatment fever subsided and convalescence proceeded normally.
Apart from drug fever, which we must call a toxic effect, the chief difficulties have been disturbance of the central nervous system, but nothing serious; there have been at least two cases of mental disturbance with hysterical fits which we have never previously seen, but our psychiatrist was not convinced that any one of them was (lue to the drug. We should normally expect about two cases in 100 to present mental symptoms. In some of the patients headache has occurred, slight dizziness, visual disturbance, occasionally spots in front of the eyes, slight dimness of vision, pareesthesia and, in one case, diminution of tactile sensibility. In two of the cases there was slight jaundice. We have not seen anmemia, but we have not made routine blood-counts. With one exception no case suggested the development of anmemia. Nor have we detected agranulocytosis. Morbilliform rashes, such as have been associated with fever in America, have not occurred.
Our conclusion about these toxic effects is that we must recognize them, and I think we shall have to conclude that some patients have an idiosyncrasy to this drug. It seems desirable that these drugs should not be sold over the counter, and that they should only be used on medical prescription, and rarely given for more than two weeks. They certainly should not be used as a " shot in the dark " for the treatment of infections in which we have no reason to suppose the drugs would do any good. Nor should they be used casually for obstetric prophylaxis. Their use is justified in certain circumstances in which there is special danger of haemolytic streptococcus infection.
Our experience-so far as it goes-supports that of the Americans in that we believe that the drugs are better tolerated by patients in bed than by those who are up and about. It is well to keep in mind that all the samples of the drugs on the market may be uniform in composition. This is suggested to me by the varying accounts of toxic effects which are coming in. The Americans have seen morbilliform rashes and we have not; others have not seen cyanosis at all; we have.
Finally, may I remind you that when Ehrlich was here in 1913 he told us we must be prepared to run some risks if we were going to do effective chemotherapy. We should remember the lesson of " 606 ". Since it was realized that " 606 " might have toxic effects, the manufacturers went to work to produce a substance which was less toxic, in fact which became less and less toxic and less and less curative. Possibly the same will happen in regard to these drugs and we should be on our guard against it.
Dr. G. A. H. Buttle: As Dr. Colebrook has dealt with the use of these drugs in infections due to hiemolytic streptococci, I shall try to present evidence of their usefulness in other infections. I shall refer to some new compounds and finallv, refer to what we know of the mode of action of sulphanilamide.
Non-ha?molytic streptococcus-In the treatment of non-haemolytic infectionis (endocarditis with S. viridans) the results have been uniformly negative. Eight strains of these organisms, however, kindly supplied by Dr. Elliot, were almost as susceptible to the drug in broth medium and in blood in vitro, as the h.Tmolytic streptococcus; one, of the S. fcecalis type, was not susceptible. It is possible that the lack of therapeutic effect is due to the low phagocytic power of the blood ofthe patients, or it may be that the streptococci in the heart valves are inaccessible to the drug.
Meningococcus.-In mice the results have been very striking. Mice infected witl 1,000,000 fatal doses can be cured with sulphanilamide (compared with 10,000 in the case of mice infected with haemolytic streptococci). It is not necessary to continue the administration of the drug, as one dose is almost as effective as repeated doses. The results of delaying treatment for two to five hours after infection are not as good. however, as with streptococcal infections (Proom [14] ). Since the drug gets into the cerebrospinal fluid in almost as high a concentration as into the blood, good results might be expected in meningococcal meningitis. There is, as yet, very little clinical evidence of its value, but Schwentker et al. [16] have published the results of ten cases. nine of which were successfully treated. It seems possible that the treatment may fail if started late in the disease, as large amounts of toxic substance may have already been formed; these are not neutralized by the drug, the only effect of which is on t,he growth of the cocci. In the one failure reported by Schw-entker the fluid(l was sterile after the treatment.
Gonococcus.-In in vitro experiments gonococci are as suseeptible to the action of the drug as meningococei. There are, as yet, no experiments published in animals. wAith the exception of one report by Levaditi and Vaisman [12] . There have been a number of clinical reports (Dees and Colston [5] , Crean [4] , Von Griitz [17] , and Anwyl-Davies [1] ). All these authors, except Aniwyl-Davies, find that the use of sulphanilamide or its derivatives shortens the period of treatment to abolut one half of the usual time, but there are a few failures reported by each of the workers. Anwvl Davies finds that sulphanilamide is without effect.
Typhoid coli group.- Figure 1 shows that sulphanilamide cures mice infected with about 100 fatal doses of B. typhosus. One dose of the drug gives as good a, result as repeated doses (Buttle et al. [3] ), although the mouse blood contains living B. typhosus for very long periods, up to two weeks after the infection. There have been as vet no clinical trials of the drug in this infection.
The second part of figure 1 shows that sulphanilamni(le has a pronounced effect, in Sonne dysentery infections of mice; infections with 10,000 lethal doses can be cured. This suggests that sulphanilamide may be uesfuil in the control of the infantile diarrhcea which is sometimes due to this organism. We have not yet obtained Shiga, or Flexner strains of sufficient, virtulence to enable us to test the effect of the drug in these infections.
From the clinical standpoint the most striking therapeutic results have been obtained in urinary infections with B. coli (Huber [10] , Kenny [11] , and Helmholtz [9] ) ; the last author also finds that B. proteus infections are particularly susceptible. On the other hand, urinary infections with S. fmecalis are insusceptible to sulphanilamide, but are readily treated with mandelic acid.
Staphylococcus.-There is, as yet, no clinical evidence published with regard to the treatment of staphylococcal infections in man, but it is possible to cure mice infected intraperitoneally w-ith virulent strains, in suspension with 500 mucin. Figure 2 shows experiments by Dr. Parish and mvself. 8000 of the animals infected with 100 lethal doses of a virulent staphylococeus (bovine mastitis) could be 6 154 7 Section of Medicine with Section of Therapeutics and Pharmacology 155 kept alive for forty-eight days, but on post-mortem examination at the end of this time half of these animals were found to contain staphylococcal abscesses the other half showed no lesions and cultures were sterile. With 10,000 lethal doses there was only a delay in the time of death, and the staphylococcal abscesses were numerous. Dose.-Staphylococci-25 mgm. of sulphanilamide twice daily for seven days. Streptococci-50 mgm. of sulphanilamide once daily on 1st, 2nd, 3rd, 4th, 6th, 9th, and 12th days.
All animals infected with staphylococci and dying after treatment showed a number of abscesses; of those that survived half showed abscesses on post-mortem examination.
The mice cured of streptococcal infection were free from organisms. See fig. 1 for further explanation. Figure 2 also shows a comparison between the results of treating staphylococcal and streptococcal infections of approximately equal virulence. The staphylococcal infection was much more difficult to get rid of than the streptococcal, probably owing to the tendency to the formation of local abscesses. From this evidence we should not expect as good clinical results in the treatment of staphylococcal as in streptococcal infections, although in our mouse experiments with virulent strains sulphanilamide gave better results than antitoxic serum.
Domagk [6] has recently published results with the compound ' uliron" NH2 01I3> 802 NH K7O N(CH3)2. This compound is said to give better results in staphylococcal and gas-gangrene infections than sulphanilamide. Gas gangrene. There is one clinical report (Bohlman [2] ) of three cases of gasgangrene infection successfully treated with sulphanilamide: in one case the recovery Mwas dramatic.
Pneumnococcus.-Gross and Cooper [7] have reported that sulphanilamide cures rats infected intranasally w-ith Type III pneumococci. In a preliminarv report Heintzelman et al. [8] found that the drug was useful clinically.
In infections of mice with pneumococci Types I and II sulphanilamide only (lelays death (Buttle et al. [3] ), although there is a great variation in the susceptibilitv of different strains as indicated bv the results of Rosenthal Figure 3 shows that the benzylidene Schiff's base of 4:4'diaminodiphenylsulphone (a compound made by my colleague Mr. Gray) is more effective, although the results are not comparable to those with sulphanilamide in streptococcal infections. This difference between the drugs is probably due to the maintenance of a more constant bactericidal effect in the mouse with the sulphone ; it is possible that the difference would not be so marked in human infections.
The mice which were cured of this infection were immune to a further infection. In similar experiments with streptococci the mice did not become immune. As there is little difference between the susceptibility of the streptococcus and the pneumococcus to sulphanilamide in vitro it is possible that the failure in therapeutic experiments with the pneumococcus-delayed death-time instead of complete protection-may depend on the production of more noxious toxic substances by the small number of cocci which remain in the treated animals. Table I shows that if sulphanila.mide is given to mice infected with pneumococcus Type I immediately after infection they can be saved with small amounts of antitoxic serum given eighteen hours afterwards, whereas much larger quantities of serum are ineffective without sulphanilamide. Sulphanilamide given at the same time as the it is not at all toxic to mice. Clinical trials Inow in progress in France indicate that this substance is just as effective in human gonococcal infections as sulphanilamide, whilst it gives less trouble owing to its lower toxicity [13] .
Mode of action. -Table II shows that sulphanilamide has only a small effect in by 0 5 c.c. blood + 0.5% sulphanilamide 500,000 50* 50* * Growth of larger nuimber delayed. killing streptococci in blood from which the leucocytes have been removed, although it will delay the growth of large numbers. Its principal function appears to be delaying the growth of the cocci, and possibly damaging them in some way which promotes their phagocytosis. The means by which the damage is done is still unknown. Figure 4 (p. 9) shows the rate of multiplication of 1,200 cocci in blood with and without leucocytes and in similar specimens containing sulphanilamide. The striking feature is that there is no difference in the first two hours of incubation; the action of the drug on the cocci only comes on very slowly. In blood without leucocytes there is no phase of reduction of numbers comparable to that obtained in the presence of leucocytes. (All these experiments were done in 1 c.c. ampoules with tight cottonwool plugs; the ampoules were rotated once a minute.)
Dr. M. Mitman: My contribution to this discussion is an account of soine simple clinical trials of the benzyl derivative in the practice of a fever hospital. In the infectious diseases the importance of the haemolytic streptococcus cannot be overemphasized. Apart from its role as the primary motiological agent in puerperal fever, scarlet fever, and erysipelas, it is responsible, as a secondary organism, for a high percentage of the complications in other infectiouis diseases. Otitis media, mastoiditis, adenitis, bronchopneumonia, and empyema, in slch diseases as nmcasles and whoopingcough, are almost invariably due to homolytic streptococci, and those septic complications which occasionally occur in diphtheria and other fevers are frequently due to the same organism. Since these complications are responsible for a considerable amount of the morbidity and mortality in infectious diseases, the appearance of a successful chemotherapeutic agent against the hawmolytic streptococcus promised to be of considerable importance in fever practice. Scarlet fever and erysipelas were the obvious first choice in trying out the new (Irug.
In scarlet fever the haemolytic streptococcus produces clinical manifestations which, for convenience, may be divided into toxic and invasive ones. This distinction is to a certain extent artificial, but it serves at least one useful purpose: it permits the divisioni of the clinical features illto those which bare rea(lily influenced by serum anid those wlhich are not. There is to-day general agreement that scarlatinal antitoxic serum rapidly neutralizes the general anld local toxic manifestations such as pyrexia, headache, mcalaise, vomiting, sore throat, ain(l the rash, and influences the anmount and extent of the subsequent desquamationi. On the other lha,nid, there is still considerable divergence of opinion as to the value of serum in the prevention and treatment of complications such as otitis media, adenitis, rhinitis, nephritis, arthritis, and septicoemia all of which are usually attributed to the invasive properties of the streptococcus. When the opening speakers and their collaborators reported their early success with the original prontosil in puerperal septicomia in which disease the invasive character of the hamolytic streptococcus is of paramlount importance-it seemed a reasonable inference that the druig might influence the complications of scarlet fever. The investigation I am recording was therefore undertaken with the object of determining if all the clinical manifestations of scarlet fever could be wiped out-the toxic ones by the administration of serum, and the invasive ones by sulphanilamide. There was, however, one obvious objection. Scarlet fever to-day is a relatively mild disease with a trivial fatality rate. When the investigation began in July 1936, reports of the toxic effects of the drug were accumulating, and there was a distinct possibility that the treatment would be more dangerous than the disease. At this time it was represented to me that the benzyl derivative, proseptasine, was less toxic than the prontosil-red then marketed, and I decided to use it instead, even if it should prove to be less active.
The cases of scarlet fever investigated numbered 355, and were divided into three groups. The first was a control group; the second received antiscarlatinal serum; the third received both serum and proseptasine. To eliminate as far as possible other variable factors which are known to influence the result of treatment, e.g. age, season, severity of the attack, nursing and medical attention, the following procedure was adopted:
Four wards were reserved for the investigation and were placed in the charge of one medical officer-Dr. J. C. Hogarth. In each of the wards patients were allotted to the three groups in strict rotation. Treatment did not begin until the cases had been seen and graded by Dr. Hogarth. This meant that, for uniformity, treatment was not instituted until the morning after admission. All doubtful cases and all cases of surgical scarlet fever were excluded, as were all cases suffering from intercurrent conditions unrelated to scarlet fever and likely to influence the duration of the pyrexia and the stay in hospital. Two cases were excluded from the control series because their original toxaemia was sufficiently severe and prolonged to give rise to some anxiety, and it became a moral obligation to administer serum. This, of course, affected the results in the control group advantageously-particularly as the number of severe cases in the series is small.
After preliminary cautious trials the dosage of proseptasine decided upon was the following:
Children under 5 years of age were given 0 5 grm. twice daily for three days, followed by 0-5 grm. once daily for four days. On the sixteenth day of the disease a second course of 0-5 grm. daily began, and was continued for seven days.
Children over 5 years of age were given 05 grm. three times a day for three days, followed by 0 5 grm. twice a day for four days. The second course from the sixteenth day onwards was 0 5 grm. twice a day for seven days.
The object of the two courses was to cover those periods of the illness in which clinical manifestations commonly occur. The first course was intended for the treatment of the initial symptoms and the early complications, the second for the prevention and treatment of the later complications which commonly appear in the third week of the disease.
The effect of the treatment was judged from two criteria: the duration of the initial pyrexia, and the incidence of complications. The initial pyrexia was considered to be over when the temperature had remained normal for twenty-four hours or more. This is, of course, an arbitrary standard, but it was applied equally to all three groups. The first day of admission was counted as one day, irrespective of the time of the day the patient was admitted. As the personal element is of some importance in determining the presence of complications, the decision in every case was left to one observer-(Dr. Hogarth).
The results were disappointing (see Dr. Hogarth's tables of the chief findings, p. 17). No significant difference was observed in the duration of the initial pyrexia or in the appearance of the complications. The tables do show some differences, but the original aim was to eliminate complications, and in this respect the experiment was a failure. I will leave the discussion on this until I have described the results in erysipelas.
Whilst the work on scarlet fever was proceeding, proseptasine was-tried in various other conditions, including erysipelas, and the results were promising.
From January 1 to October 1, 1937, 59 cases of erysipelas were treated with proseptasine. The age-distribution is given in Table I . The ages of the patients EASTERN HOSPITAL, JANUARY 1 TO OCTOBER 1, 1937. Proseptasine in Brysipelas. The differences in numbers between the sexes was due to greater amount of ward accommodation for females.) Five cases had had previous attacks of erysipelas. One had had six previous attacks, another three, and a third two.
The anatomical distribution of the lesions is given in Table II proseptasine employed was 1 to 1-5 grm. three or four times a day. At the beginning this was continued daily for as short a time as three days in those who responded rapidly, but later, when experience had shown that relapses occurred readily, the treatment was continued for seven or more days. Two patients had received antistreptococcus serum before admission. Sulphanilamide or related substances have by now been widely used in erysipelas, aind all the results reported have been favourable. The largest recorded group treated with the benzyl derivative was that of Bloch-Michel, Conte, and Durel, which consisted of 180 cases. My results are in close agreement with theirs.
Although mine was not a controlled series, previous experience of serious cases of erysipelas warrant me to say with certainty that the results were excellent. Among the 59 cases there were 9, mostly elderly patients, who were seriously ill, but there were no deaths. The fatality rate of erysipelas of the extremities is usually given as 20%. There were 9 such cases in this series and all recovered. To me, the most striking feature of treatment with proseptasine is that, since its introduction, patients with the disease have ceased to give me any serious anxiety.
The first effect, usually observable within twenty-four hours, is a cessation of spread of the patch. Indeed, if this does not occur I take it as an indication to increase the dose. T4ere is a rapid improvement in the toxic symptoms; the temperature usually falls to normal in twenty-four to forty-eight hours, and the erythematous plaque fades in three or four days. The duration of stay in hospital is, in consequence, considerably diminished, most patients being fit to go home in about a fortnight. As an example, I will quote the case of a woman aged 72 with erysipelas of the nose and leg. The condition was complicated by the presence of senile myocarditis and bronchitis. She was seriously ill on admission and was given 1 grm. of proseptasine three times a day. She was fit and discharged from hospital in nine days.
In Table III the frequency distribution of the duration of stay in hospital is given. The high percentage of cases discharged within a fortnight can readily be seen. EASTERN One point which requires emphasis is the liability of the disease to relapse after the cessation of treatment. In this series four cases relapsed, one of them on two occasions. In two patients the relapses occurred in hospital. The first was a woman aged 57 who had a moderate attack of facial erysipelas and was treated with 3 grm. a day. In three days the temperature was normal, the patch had disappeared, and treatment was stopped. Three days later a relapse occurred and the eruption reappeared, but after two days of further treatment it cleared up. The second was a man who received 4-5 grm. a day for ten days. The relapse appeared ten days after the proseptasine was stopped, and responded readily to further treatment. In the literature recurrences are recorded in both animals and man. Long and Bliss report that in mice there may be relapses as long as sixty days after the cessation of treatment. It is therefore necessary to persevere with the drug for several days after the symptoms subside. Now I want to consider the reasons for the failure of the drug in scarlet fever. In view of the success in erysipelas, I think one can exclude inactivity of the drug and inadequate dosage as possible causes, although I am now of the opinion that the first course of treatment should have been longer-say, ten days. Another possibility is that the standards by which the effects were judged, namely the duration of the initial pyrexia and the frequency of complications, were inadequate for a proper assessment of the results. There is, I think, some substance in this objection, but there can be no doubt that the drug failed to eliminate complications, and this was the original object of the experiment. Peters and Havard report a controlled series of cases of scarlet fever treated with proseptasine. It is true that they found a significant difference in the number of cases which developed complications, but the sum of the individual complications was almost identical in the test and control groups. We are left, then, with the probability that the haemolytic streptococci responsible for scarlet fever are relatively more resistant to the drug than other pathogenic hsemolytic streptococci. The reports of Colebrook and Kenny, Long and Bliss, and Finklestone-Sayliss, Paine and Patrick all indicate that the action of sulphanilamide varies, not only with the group, type, and strain, but even with the age or phase of a particular strain. Poor effects are recorded upon haemolytic streptococci of low-mouse virulence. It is therefore not unreasonable to suggest that the strain, or strains, responsible for the mild scarlet fever now prevalent, are either unaffected or little influenced by proseptasine.
Singularly few toxic effects of the drug were observed. No routine examinations of the blood were made, but there were no cases with gross clinical evidence of damage to the blood or blood-forming organs. No cyanosis was seen, and even the mild toxic symptoms were rare. The chief toxic manifestation was a rash, which occurred in five cases. Cutaneous manifestations of various kinds have been reported by Menville and Archinard, Goodman and Levy, Frank, Schonberg, Newman and Sharlet, and others, but the account which most closely agrees with the type of eruption seen in this series was that of Schwentker and Gelman. The rashes, which usually come on ten to fourteen days after treatment began, were maculo-papular ones, most closely resembling rubella at the beginning, but later becoming more morbilliform. In distribution they were usually, but not invariably, generalized. They were not limited to, or more profuse on, the parts exposed to sunlight. General disturbance and pyrexia were trivial, and the condition cleared up in about three days.
I therefore came to the conclusion that the claim made that the drug was of low toxicity was justified. I am not in a position to express an opinion on the relative efficiency of the benzyl derivative as compared with sulphanilamide. Whitby decided, from experimental evidence, that the benzyl and phenyl-propyl compounds were as effective and less toxic than sulphanilamide. My experience does permit me to say that proseptasine is easy to give, is of low toxicity, is strikingly successful in erysipelas and relatively ineffectual in scarlet fever. have been seen but none have shown any signs of oxygen lack. Sulphaomoglobinaemia has not occurred in any patient since laxatives were forbidden and low residue diets and liquid paraffin prescribed as a routine for all patients treated with the drug. Cyanosis in absence of abnormal pigments in the blood occurs in some patients, but is important only in the immediate post-operative period, when it is frequently due to pneumonia.
Professor Arthur Green said that Ehrlich's comparison of dyestuffs and drugs was rather more than an analogy.
A dyestuff must not only possess colour but must have an affinity for the substance to be dyed. Similarly, for a drug to be active it must possess a degree of toxicity and an affinity for the cell constituents.
Further, there were dyestuffs which had a differential effect, and the ideal remedy in medicine would be a substance which had an affinity for the cell constituents of the invading organism, but none for that of the host. While this ideal might never be wholly realized there were drugs nowadays which possessed a very much greater atfinity for the cell constituents of the microbes than for those of the host. All the substances mentioned in the discussion were derivatives of aniline; P-aminobenzene sulphonamide (prontosil album) might be correctly termed aniline sulphonamide. Aniline itself was highly toxic and probably had a strong affinity for all cell constituents and so could not be used.
If one put into the molecule of aniline a sulphonic acid group, thus obtaining sulphanilic acid, one entirely changed the properties. Practically all toxicity and affinity were lost, but if one went half-way and introduced the slightly acid sulphonamide group instead of the strongly acid sulphonic group, the effect to be anticipated would be as seen in the drugs under discussion.
The sulphonamide group appeared to be one which held just the right degree of acidity and solubility so that the product would show a differential attraction between the cell constituents of the microbe and the host. On some such lines as this an explanation of the therapeutic action of these compounds would probably be found.
Dr. E. P. Poulton said that when he began using these substances, Dr. E. H. Koerner, at Guy's Hospital had mastered E. W. Todd's technique of antistreptolysin titration, and it was felt that the opportunity had arisen for treating various" occult " haemolytic streptococcal infections with P-aminophenyl sulphonamide.1-"Oeult " haemolytic streptococcal infections were those in which the actual causative organisi, could not readily be identified.
A high antistreptolysin (A.S.L.) titre in the serumn was taken by I)r. Poulton and( his colleagues as evidence of occult infection and as an indication for specific treatment. He did not want his hearers to think that high A.S.L. titres were invariably present in hamolytic streptococcal diseases, beca,use in severe himolytic streptococcal septiceemia one could get low titres. Tn obvious streptococcal inifections with streptoeocci in the bloodl, which ha,d beeni successfully treated, there might be values up to 2,000 A.S.L. units. In oIne case of very severe exfoliative dermttitis, streptococei were present in the blood, and the titre was onlly 50 (normaln). P-aminophenyl sulphonamide was given, andlhe was at first pleased with the result. Later, however, the patient died anid a small abscess in the lung was found, and pus was present in the sinuses. On the other hand, there was a case of erysipelas in a diabetic patient with a large amount of serous exudation over the patches of erysipelas, in which the A.S.L. titre was 33, and yet the patient did extremely well on P-aminophenyl sulphonamide. In six days the titre had risen to 71, a rise suggestive of streptococcal infeetion, even though the titre was within normal limits. 1 NOTE.-P-aminaphenyl sulphoiiamide-sliphanilatmiide.
The cases he would group under occult hmolytic streptococcal infection were: Acute rheumatism. He had two resistant cases which seemed to do well with these substances, and there was a small girl with purpura who gave a high A.S.L. titre; this case cleared up very quickly with P-aminophenyl sulphonamide. He divided the cases of rheumatoid arthritis with high titres into (a) acute febrile, (b) chronic febrile, and (c) chronic afebrile, often with occasional spikes of temperature up to 990 and 1000 F. There were three acute cases, and all did well, though it was difficult to know whether the effect was produced by the treatment. The temperature fell gradually and there had been a previous period when nothing seemed to have any, effect. In Group (b) one woman had fever eighteen months, and during the P-aminophenyl sulphonamide treatment the temperature was lower than at any other time; two other patients did well, and in two there was no striking improvement. After the P-aminophenyl sulphonamide was stopped, the temperature rose again. In chronic afebrile cases (c) the results were uncertain though the remedy might be tried.
A point ofimportance was that there were cases of haemolytic streptococcalinfection apparently associated with other diseases-an unexpected occurrence. The patient to whose case he would refer in this connexion had abdominal actinomycosis, and ran a continuous fever for a considerable period. Deep X-rays were tolerated badly, and only small amounts of iodine could be taken. Therefore it was eventually decided to try his antistreptolysin titration; this was high. The effect of sulphanilamide was that the temperature came down in five days. The patient put on weight, was discharged to Carshalton in September, and has had no temperature since.
The temperature chart shown above is that of a girl aged 7 who previously had had bad health, with otitis media and attacks of rheumatism; she also had recently suffered from attacks of sore throat, accompanied by diarrhcea and vomiting. On admission, with high fever, she was at first considered to have B. coli communi8 pyelitis, as that organism was recovered from the urine, but there were no kidney symptoms. On the sixth day after admission the A.S.L. titration was 140, perhaps just above normal, and 1-2 grm. of P-aminophenyl sulphonamide were given that day and 6 grm. the next. A remarkable fall of temperature followed. On the tenth day the A.S.L. titre had risen to 280. When the drug was omitted the temperature again became high. The patient had been very ill, and two house physicians detected at one time a pericardial rub for quite a short period. It is ::
IL.
-L---L-suggested that in spite of the coli bacilluria, which also cleared up under P-aminophenyl sulphonamide, the temperature was really due to occult haemolytic streptococcal infection.
Dr. J. C. Hogarth said that his tables gave details of the series of 355 cases of scarlet fever referred to by Dr. Mitman. Table I w%,ould be seen that there appeared to be a iiatural selection in favour of Group I in the types classified as " mild ", " mild-moderate ", and " moderate ", but he did not think this was altogether true. Division into these three types was made in an effort to show a more accurate distribution. This was not successful because the eases in these groups were all very mild with consequent difficulty in classification. He suggested that it would be better to take the three types together under the term ; mild-moderate ". When that was done little difference would be seen between the three groups. The remaining types of case were more easily defined and could be left as they stood. It was from Group I in the type " mild-moderate " that two cases were removed. These cases proved to be so toxic that there could be no justification for withholding serum. .,,,......... ' . ' , * Xet .' 4 Ft .,'., ' *' , ** .. ,,.< 4 '|' e, *' ,e, 1039 7
